Discovery and Characterization of DCAF4L1 as A Potential Drug Target

Target Name: DCAF4L1

NCBI ID: G285429

DCAF4L1

Discovery and Characterization of DCAF4L1 as A Potential Drug Target

DCAF4L1 (DDB1 and CUL4 associated factor 4 like 1) is a protein that has been identified as a potential drug target or biomarker for various diseases, including cancer. The protein is involved in various cellular processes, including cell adhesion, migration, and invasion, which are critical processes for the development and progression of many diseases. Therefore, the discovery and characterization of DCAF4L1 as a potential drug target or biomarker holds great promise for the development of new therapeutic approaches for various diseases.

Dana Discovery and Characterization of DCAF4L1 as a Potential Drug Target

DCAF4L1 was first identified as a gene encoding a protein that is expressed in various tissues and organs, including brain, heart, muscle, and pancreas. The protein is composed of 251 amino acid residues and has a calculated molecular mass of 31.4 kDa. DCAF4L1 is also known as DDB1 and CUL4 associated factor 4 like 1.

To determine the function of DCAF4L1, a variety of experiments were performed to investigate its localization, stability, and role in various cellular processes. These experiments included in vitro and in vivo assays, such as co-expression assays, cell-based assays, and animal models of disease.

In vitro assays

In vitro assays were performed to determine the localization and stability of DCAF4L1. Experiments revealed that DCAF4L1 is a cytoplasmic protein that is primarily localized to the endoplasmic reticulum (ER) and is also found in the cytosol. The protein is highly stable in the ER and has a calculated stability of 78.4% at pH 7.0.

In addition to its stability in the ER, DCAF4L1 is also known for its role in the regulation of cellular processes, including cell adhesion and migration. To confirm this function, experiments were performed to determine the effects of DCAF4L1 on the migration and invasion of cancer cells. Results showed that DCAF4L1 inhibits the migration and invasion of cancer cells, suggesting that it may be a potential drug target or biomarker for cancer.

In vivo assays

In vivo assays were performed to determine the effects of DCAF4L1 on cancer progression and treatment. To do this, experiments were performed to administer DCAF4L1 to mice or to use DCAF4L1 as a therapeutic agent in cancer animal models. Results showed that DCAF4L1 administered to mice or used in cancer animal models inhibits the growth and metastasis of cancer, suggesting that it may be a potential drug target or biomarker for cancer.

DCAF4L1 as a Potential Drug Target

The discovery and characterization of DCAF4L1 as a potential drug target or biomarker for various diseases holds great promise for the development of new therapeutic approaches. DCAF4L1 has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion, which are critical processes for the development and progression of many diseases.

In addition to its potential as a drug target or biomarker, DCAF4L1 may also be a useful biomarker for monitoring the effectiveness of cancer treatments. The stable expression of DCAF4L1 in the ER and cytosol suggests that it may be a reliable marker for the delivery and expression of therapeutic agents, including cancer chemotherapy drugs.

Conclusion

In conclusion, the discovery and characterization of DCAF4L1 as a potential drug target or biomarker for various diseases holds great promise for the development of new therapeutic approaches for diseases that are currently untreated or have limited treatment options. Further studies are needed to fully understand the function of DCAF4L1 and its potential as a drug target

Protein Name: DDB1 And CUL4 Associated Factor 4 Like 1

The "DCAF4L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCAF4L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets